EU approves AstraZeneca Forxiga for use across the EU
Milestone therapy concerns the treatment of patients with symptomatic chronic heart failure
Read More
Tag: Forxiga
AstraZeneca’s Forxiga recommended in EU for chronic heart failure
Drug is the first heart failure medication to provide mortality benefit across entire ejection fraction range
Read More
AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease
Approval based on DAPA-CKD Phase III data
Read More
AZ’s Forxiga wins EU approval for heart failure
SGLT2 inhibitor approved for heart failure with reduced ejection fraction
Read More
FDA Fast Track granted for AZ’ Forxiga
The indication, chronic kidney disease, is a serious, progressive condition defined by decreased kidney function.
Read More
Positive results continue success for Forxiga
Forxiga has had a string of successes recently, as it was recommended by NICE and had its EU marketing authorisation updated earlier this month.
Read More
AZ’ Forxiga label updated in EU for type II diabetes
The decision comes from positive cardiovascular outcomes and renal data from the Phase III DECLARE-TIMI 58 trial.
Read More
NICE recommends Skyrizi, Forxiga
The recommendations are for the indication of plaque psoriasis and type I diabetes, respectively.
Read More
AZ bags two extensions in latest CHMP decisions
The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
Read More
EU approves AZ’ Forxiga for type I diabetes
The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes.
Read More
Forxiga receives positive EU CHMP for type I diabetes in adults
AstraZeneca’s Forxiga has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin in adults with type I diabetes.
Read More
AZ’ Forxiga to be reviewed for diabetes type I
The European Medicines Agency has accepted AstraZeneca’s filing for Forxiga as a treatment for diabetes type I.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
